It could perhaps deliver a much bigger gain than 100%.
Compare XBI Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
SPDR S&P Biotech
News & Analysis: SPDR S&P Biotech
In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing.
It definitely made investors a lot of money over the last decade. And its future could be brighter than the past.
They've both already made some investors a lot of money over the last few years.
Buying 140 biotech stocks in one fell swoop could be a winning strategy.
There's money moving back into the sector, and all boats are set to rise.
These exchange-traded funds offer investors an easy way to potentially profit from growth in the healthcare sector.
Here's why this team of biotech experts are giddy about these stocks right now.
Seven simple steps to improving your chances of success in this part of the market.
A biotech ETF, a cash-gushing large-cap, and a dirt-cheap biopharma company top our list of great stocks to buy right now.